mirzotamab clezutoclax
Generic: Mirzotamab Clezutoclax
mirzotamab clezutoclax: 1 clinical trial tracked.
mirzotamab clezutoclax evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about mirzotamab clezutoclax, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
Phase Ib Trial of ABBV-637 or ABBV-155 in Combination With ERAS-801 for Glioblastoma With Amplification of the Epidermal Growth Factor Receptor
Primary endpoint: Dose limiting toxicity (DLT)
InterventionalRandomizedopen60 targetStarted 2025-04Completion 2028-048 sites · United StatesMemorial Sloan Kettering Cancer Center